Vertex, Inc. (VERX) has disclosed a new risk, in the Debt & Financing category. Vertex, Inc. faces significant financial risk in the event of a ...

The stock's rise snapped a four-day losing streak.

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the shares. The firm had previously indicated that shares had ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

DA Davidson analyst William Jellison lowered the firm’s price target on Vertex (VERX) to $55 from $62 and keeps a Buy rating on the shares.

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

BofA lowered the firm’s price target on Vertex (VERX) to $44 from $55 and keeps a Neutral rating on the shares following Q4 results and an ...

Arc’teryx unveils its 2025 footwear lineup, featuring the Norvan LD 4, Vertex Speed, and Konseal, designed to enhance ...

It's not enough to go far or even fast. The upcoming Arc'teryx Vertex Speed trail running shoe can also travel high.